Q2041
Axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
- 2021 Status Change: Change in long description of procedure or modifier code
- Effective Date: 2018-04-01
- Medicare Coverage Status: Carrier Judgement
- BETOS Classification: Other drugs
Medicare has not assigned a fee schedule for this code
Q2040
Q2042 